Education and Clinical Decision Support: Reuniting Twins Separated at Birth Jerry Osheroff, M.D. Thomson Healthcare University of Pennsylvania.
Coumadin/Warfarin Minimizing risk and Optimizing Safety.
Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation – TIMI 48 Primary Results Robert P. Giugliano, MD, SM, FAHA, FACC On behalf.
Stroke prevention in atrial fibrillation: current limitations and novel antithrombotic agents Module 5.
ECG Notes
Br J Haematol. 2008 Jun;141(6):757-63. A review of guidelines and update in emerging therapies Brian Spoelhof, PharmD April 19, 2012.
CLINICAL CASES. Atrial Fibrillation Case Study #2 ► An 81-year-old white female with a history of chronic, non-valvular AF, a history of a previous ischemic.
1 Dr. Mario Fitz Maurice Electrofisiología Cardíaca Hospital Rivadavia [email protected] AF AC Anticoagulation in Atrial Fibrillation.
ARISTOTLE TRIAL Dr R Nyabadza GPST1 Ward 32. Structure AF, stroke and CHA 2 -DS 2 VASC Anticoagulant choices ARISTOTLE trial Cost NICE guidance and the.
Cranberry Vaccinium macrocarpon-cultivated in Washington Long history of use The mechanism was thought to be urine acidification Now E. coli (other pathogens.
Decreasing Stroke Risk in AF October 13 2011 Mario L Maiese DO FACC FACOI Associate Professor UMDNJSOM South Jersey Heart Group Email @ [email protected]@comcast.net.
Venous thromboembolism: how long to treat? Eliot Williams, MD PhD Department of Medicine Division of Hematology & Medical Oncology.
